Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications

S. Chiaretti, M. Messina, S. Grammatico, A. Piciocchi, AL. Fedullo, F. Di Giacomo, N. Peragine, V. Gianfelici, A. Lauretti, R. Bareja, MP. Martelli, M. Vignetti, V. Apicella, A. Vitale, LS. Li, C. Salek, O. Elemento, G. Inghirami, DM. Weinstock,...

. 2018 ; 181 (5) : 642-652. [pub] 20180419

Language English Country England, Great Britain

Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc19012715

BCR/ABL1-like acute lymphoblastic leukaemia (ALL) is a subgroup of B-lineage acute lymphoblastic leukaemia that occurs within cases without recurrent molecular rearrangements. Gene expression profiling (GEP) can identify these cases but it is expensive and not widely available. Using GEP, we identified 10 genes specifically overexpressed by BCR/ABL1-like ALL cases and used their expression values - assessed by quantitative real time-polymerase chain reaction (Q-RT-PCR) in 26 BCR/ABL1-like and 26 non-BCR/ABL1-like cases to build a statistical "BCR/ABL1-like predictor", for the identification of BCR/ABL1-like cases. By screening 142 B-lineage ALL patients with the "BCR/ABL1-like predictor", we identified 28/142 BCR/ABL1-like patients (19·7%). Overall, BCR/ABL1-like cases were enriched in JAK/STAT mutations (P < 0·001), IKZF1 deletions (P < 0·001) and rearrangements involving cytokine receptors and tyrosine kinases (P = 0·001), thus corroborating the validity of the prediction. Clinically, the BCR/ABL1-like cases identified by the BCR/ABL1-like predictor achieved a lower rate of complete remission (P = 0·014) and a worse event-free survival (P = 0·0009) compared to non-BCR/ABL1-like ALL. Consistently, primary cells from BCR/ABL1-like cases responded in vitro to ponatinib. We propose a simple tool based on Q-RT-PCR and a statistical model that is capable of easily, quickly and reliably identifying BCR/ABL1-like ALL cases at diagnosis.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012715
003      
CZ-PrNML
005      
20240516084445.0
007      
ta
008      
190405s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bjh.15251 $2 doi
035    __
$a (PubMed)29675955
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Chiaretti, Sabina $u Haematology, Department of Cellular Biotechnologies and Haematology, "Sapienza" University, Rome, Italy.
245    10
$a Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications / $c S. Chiaretti, M. Messina, S. Grammatico, A. Piciocchi, AL. Fedullo, F. Di Giacomo, N. Peragine, V. Gianfelici, A. Lauretti, R. Bareja, MP. Martelli, M. Vignetti, V. Apicella, A. Vitale, LS. Li, C. Salek, O. Elemento, G. Inghirami, DM. Weinstock, A. Guarini, R. Foà,
520    9_
$a BCR/ABL1-like acute lymphoblastic leukaemia (ALL) is a subgroup of B-lineage acute lymphoblastic leukaemia that occurs within cases without recurrent molecular rearrangements. Gene expression profiling (GEP) can identify these cases but it is expensive and not widely available. Using GEP, we identified 10 genes specifically overexpressed by BCR/ABL1-like ALL cases and used their expression values - assessed by quantitative real time-polymerase chain reaction (Q-RT-PCR) in 26 BCR/ABL1-like and 26 non-BCR/ABL1-like cases to build a statistical "BCR/ABL1-like predictor", for the identification of BCR/ABL1-like cases. By screening 142 B-lineage ALL patients with the "BCR/ABL1-like predictor", we identified 28/142 BCR/ABL1-like patients (19·7%). Overall, BCR/ABL1-like cases were enriched in JAK/STAT mutations (P < 0·001), IKZF1 deletions (P < 0·001) and rearrangements involving cytokine receptors and tyrosine kinases (P = 0·001), thus corroborating the validity of the prediction. Clinically, the BCR/ABL1-like cases identified by the BCR/ABL1-like predictor achieved a lower rate of complete remission (P = 0·014) and a worse event-free survival (P = 0·0009) compared to non-BCR/ABL1-like ALL. Consistently, primary cells from BCR/ABL1-like cases responded in vitro to ponatinib. We propose a simple tool based on Q-RT-PCR and a statistical model that is capable of easily, quickly and reliably identifying BCR/ABL1-like ALL cases at diagnosis.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    12
$a bcr-abl fúzní proteiny $x biosyntéza $x genetika $7 D016044
650    12
$a regulace genové exprese u leukemie $7 D015973
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a novorozenec $7 D007231
650    _2
$a mužské pohlaví $7 D008297
650    12
$a biologické modely $7 D008954
650    12
$a akutní lymfatická leukemie $x diagnóza $x genetika $x metabolismus $x mortalita $7 D054198
650    _2
$a prediktivní hodnota testů $7 D011237
650    12
$a kvantitativní polymerázová řetězová reakce $7 D060888
650    _2
$a míra přežití $7 D015996
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Messina, Monica $u Haematology, Department of Cellular Biotechnologies and Haematology, "Sapienza" University, Rome, Italy.
700    1_
$a Grammatico, Sara $u Haematology, Department of Cellular Biotechnologies and Haematology, "Sapienza" University, Rome, Italy.
700    1_
$a Piciocchi, Alfonso $u GIMEMA Data Centre, GIMEMA Foundation, Rome, Italy.
700    1_
$a Fedullo, Anna L $u Haematology, Department of Cellular Biotechnologies and Haematology, "Sapienza" University, Rome, Italy.
700    1_
$a Di Giacomo, Filomena $u Haematology, Department of Cellular Biotechnologies and Haematology, "Sapienza" University, Rome, Italy. Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.
700    1_
$a Peragine, Nadia $u Haematology, Department of Cellular Biotechnologies and Haematology, "Sapienza" University, Rome, Italy.
700    1_
$a Gianfelici, Valentina $u Haematology, Department of Cellular Biotechnologies and Haematology, "Sapienza" University, Rome, Italy.
700    1_
$a Lauretti, Alessia $u Haematology, Department of Cellular Biotechnologies and Haematology, "Sapienza" University, Rome, Italy.
700    1_
$a Bareja, Rohan $u Department of Physiology and Biophysics, Weill Cornell Medical College, New York, NY, USA.
700    1_
$a Martelli, Maria P $u Institute of Haematology, Centro Ricerche Onco-Ematologiche (CREO), University of Perugia, Perugia, Italy.
700    1_
$a Vignetti, Marco $u Haematology, Department of Cellular Biotechnologies and Haematology, "Sapienza" University, Rome, Italy.
700    1_
$a Apicella, Valerio $u Haematology, Department of Cellular Biotechnologies and Haematology, "Sapienza" University, Rome, Italy.
700    1_
$a Vitale, Antonella $u Haematology, Department of Cellular Biotechnologies and Haematology, "Sapienza" University, Rome, Italy.
700    1_
$a Li, Loretta S $u Department of Paediatric Haematology/Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
700    1_
$a Salek, Cyril $u Institute of Haematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Elemento, Olivier $u Department of Physiology and Biophysics, Weill Cornell Medical College, New York, NY, USA.
700    1_
$a Inghirami, Giorgio $u Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.
700    1_
$a Weinstock, David M $u Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
700    1_
$a Guarini, Anna $u Department of Molecular Medicine, "Sapienza" University, Rome, Italy.
700    1_
$a Foa, Robin $u Haematology, Department of Cellular Biotechnologies and Haematology, "Sapienza" University, Rome, Italy. $7 xx0317383
773    0_
$w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 181, č. 5 (2018), s. 642-652
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29675955 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20240516084439 $b ABA008
999    __
$a ok $b bmc $g 1392025 $s 1051020
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 181 $c 5 $d 642-652 $e 20180419 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
LZP    __
$a Pubmed-20190405

Find record

Citation metrics

Archiving options